NUTCRACKER Logo (WIPO, 03/17/2021)
WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark NUTCRACKER was filed as Figurative mark on 03/17/2021 at the World Intellectual Property Organization.
Logodesign (Wiener Klassifikation)
#Armillary spheres, planetaria, astronomic orbits, atomic models, molecular models #Knives, forks and spoons, kitchen utensils and machines #Letters or numerals representing a human being, an animal, a plant, a heavenly body, a natural phenomenon or an object #Atomic models, molecular models, representations of human, animal or vegetal cells #Kitchen utensils and machines #Other kitchen utensils or machines, moulds #Letters or numerals representing a figurative element
| Trademark form | Figurative mark |
| File reference | 1605646 |
| Countries | 
|
| Base trademark |
No. ,
October 18, 2024
|
| Application date | March 17, 2021 |
| Expiration date | March 17, 2031 |
Trademark owner
5858 Horton Street, Suite 540
Emeryville CA 94608
US
Emeryville CA 94608
US
Trademark representatives
5 Columbia Circle
Albany NY 12203
US
goods and services
01
Active chemical ingredients, including m-RNA, for use in the
manufacture of anti-cancer drugs; chemical solutions and
preparations consisting of pre-mixed reactants and reagents
for scientific and research use in connection with
transcription and translation of nucleic acid; chemical
solutions and preparations consisting of pre-mixed reactants
and reagents used to transfect nucleic acid into cells in
the field of scientific research; active chemical
ingredients for use in manufacture of anti-cancer drugs;
protein arrays and nucleotide arrays for scientific use;
nucleic acids, proteins and peptides for laboratory use;
diagnostic preparations for scientific or research use other
than for medical purposes; macromolecules, namely, nucleic
acid sequences and proteins, used for pharmaceutical
manufacturing and scientific purposes
05
Macromolecules, namely, nucleic acid sequences and proteins,
used for medical purposes; nucleic acid sequences and
chemical reagents for medical purposes; protein arrays and
nucleotide arrays for medical laboratory use; diagnostic
preparations for clinical or medical laboratory use
09
Cartridges and DNA chips to receive and preserve biological
samples for use in RNA transcription; scientific apparatus
and instruments for manufacturing m-RNA and parts and
fittings therefore; laboratory apparatus and instruments for
transcription of RNA from DNA and translation to m-RNA;
scientific apparatus for receiving DNA samples, transcribing
RNA, and producing m-RNA molecules for use in identifying
and/or manufacturing therapeutic drugs to treat human
diseases
35
Business consulting and management in the field of clinical
trials, namely, clinical data and regulatory submission
management on behalf of medical, biopharmaceutical and
biotechnology companies to assist them with clinical
research, clinical trials and applications for drug
approval; compiling data for research purposes in the field
of medical science and medical consultancy
42
Consulting services in the fields of biotechnology,
pharmaceutical research and development and genetic
sciences; DNA analysis services for scientific research
purposes; medical and scientific research, in particular in
the fields of prevention and treatment cancer; providing
scientific research information, consultancy, and advisory
services, in particular in the fields of prevention and
treatment of cancer treatment; conducting early evaluations
in the field of new pharmaceuticals; consulting services in
the fields of biotechnology and pharmaceutical research;
pharmaceutical product development services; pharmaceutical
product evaluation services; pharmaceutical research and
development; providing medical and scientific research
information in the field of pharmaceuticals and clinical
trials; research and development of pharmaceuticals for the
treatment of cancer; technical research in the field of
pharmaceutical studies; development of platform technology,
namely, cancer immunotherapy platforms for manufacturing
therapeutics; and consulting services for others in the
field of design, planning, and implementation of clinical
trials; design, engineering, research, development and
testing services in the field of nucleic acid sciences for
medical, scientific and technological applications;
scientific research; scientific research in the fields of
pharmaceuticals, medicine, biologics, biotherapeutics,
biosimilars and therapeutics
44
Medical services, in particular providing therapy and
vaccination approaches for treating and preventing cancer,
infectious diseases and immunological diseases; veterinary
services, in particular providing therapy and vaccination
approaches for treating and preventing cancer, infectious
diseases, and immunological diseases; medical, veterinary
and pharmaceutical consultation; medical and veterinary
diagnostic testing, monitoring and reporting services;
providing medical information, consultancy, and advisory
services, in particular in the fields of treatment and
prevention of immunological diseases, cancer treatment,
prevention of cancer, treatment of infectious diseases, and
prevention of infectious diseases; medical services, namely,
providing therapies for treating cancer, medical and
pharmaceutical consultation; medical diagnostic testing,
monitoring and reporting services; genetic testing for
medical purposes
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| March 13, 2023 | 2023/11 Gaz | KR | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| January 25, 2023 | 2023/4 Gaz | MY | Rejection |
| January 17, 2023 | 2023/6 Gaz | SG | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| November 17, 2022 | 2022/46 Gaz | CA | Rejection |
| November 3, 2022 | 2022/45 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| September 19, 2022 | 2022/42 Gaz | IN | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| September 16, 2022 | 2022/37 Gaz | AU | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| August 19, 2022 | 2022/34 Gaz | ID | Rejection |
| August 4, 2022 | 2022/31 Gaz | KR | Rejection |
| June 28, 2022 | 2022/26 Gaz | CH | Rejection |
| May 11, 2022 | 2022/19 Gaz | GB | Rejection |
| April 28, 2022 | 2022/17 Gaz | JP | Rejection |
| March 1, 2022 | 2022/9 Gaz | CN | Rejection |
| January 4, 2022 | 2022/1 Gaz | EM | Rejection |
| October 2, 2021 | 2021/41 Gaz | SG | Rejection |
| August 19, 2021 | 2021/34 Gaz | IN | Rejection |
| August 14, 2021 | 2021/33 Gaz | AU | Rejection |
| March 17, 2021 | 2021/29 Gaz | US | Registration |
ID: 141605646